The multifaceted role of beta-blockers in overcoming cancer progression and drug resistance: Extending beyond cardiovascular disorders.

Autor: Cavalu S; Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania., Saber S; Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt., Amer AE; Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt., Hamad RS; Biological Sciences Department, College of Science, King Faisal University, Al Ahsa, Saudi Arabia.; Central Laboratory, Theodor Bilharz Research Institute, Giza, Egypt., Abdel-Reheim MA; Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Shaqra, Saudi Arabia.; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni Suef, Egypt., Elmorsy EA; Department of Pharmacology and Therapeutics, College of Medicine, Qassim University, Buraidah, Saudi Arabia.; Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura, Egypt., Abdelhamid AM; Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt.
Jazyk: angličtina
Zdroj: FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2024 Jul 15; Vol. 38 (13), pp. e23813.
DOI: 10.1096/fj.202400725RR
Abstrakt: Beta-blockers are commonly used medications that antagonize β-adrenoceptors, reducing sympathetic nervous system activity. Emerging evidence suggests that beta-blockers may also have anticancer effects and help overcome drug resistance in cancer treatment. This review summarizes the contribution of different isoforms of beta-adrenoceptors in cancer progression, the current preclinical and clinical data on associations between beta-blockers use and cancer outcomes, as well as their ability to enhance responses to chemotherapy and other standard therapies. We discuss proposed mechanisms, including effects on angiogenesis, metastasis, cancer stem cells, and apoptotic pathways. Overall, results from epidemiological studies and small clinical trials largely indicate the beneficial effects of beta-blockers on cancer progression and drug resistance. However, larger randomized controlled trials are needed to firmly establish their clinical efficacy and optimal utilization as adjuvant agents in cancer therapy.
(© 2024 The Author(s). The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.)
Databáze: MEDLINE
Externí odkaz: